 |
 |
|
|
| |
Graffinity - fragment based
drug discovery
 Graffinity is the premier partner for fragment
based drug discovery and lead development of small molecule
pharmaceuticals. Graffinity has built a unique approach which includes
chemical microarrays, fragment screening, SPR label-free imaging of
protein-ligand interactions, computational chemistry and lead
discovery. The technology platform offers a new drug discovery paradigm
for the rapid conversion of genomic information into novel, high
quality leads and drug candidates.
Graffinity applies this technology in established high-profile
collaborations with leading Pharma and Biotech companies.
NovAliX has acquired a majority interest in Graffinity.
Graffinity's proprietary Fragment-Based SPR Drug Discovery technology
will be added to NovAliX's integrated chemistry and biophysical
capabilities.
 read more ...
|
| |
|
|
|
|
|
|
| |
 |
|
Press Releases:
|
|
 January 12, 2012:
NovAliX/Graffinity enters into multi-target, integrated drug discovery collaboration with Teijin Pharma
read more ... |
|
August 29, 2011:
NovAliX/Graffinity and Galapagos collaborate in Osteoarthritis discovery research program
read more ... |
|
March
30, 2011:
Graffinity enters into drug discovery collaboration with Shionogi
read more ... |
|
|
Archive
Press Releases |
|
|
|
|
|
|
